Abstract |
Bisantrene (Bis), a topoisomerase-II inhibitor, is less cardiotoxic than the current anthracyclines. Its synergistic cytotoxicity with newly developed antineoplastic drugs has not been reported. We demonstrated the synergism of [Bis + ABT199/ venetoclax] in combination with panobinostat (Pano), decitabine (DAC), or olaparib (Ola), known inhibitors of BCL2, histone deacetylase, DNA methyltransferase, and poly(ADP-ribose) polymerase, respectively, in AML cells. [Bis + ABT199] with Pano, DAC, or Ola synergistically inhibited cell proliferation with combination indices of 0.25-0.6, 0.2-0.35, and 0.2-0.4 (at 50% inhibition of proliferation), respectively. Increased γ-H2AX suggests enhanced DNA damage; cleavages of Caspase 3 and PARP1, DNA fragmentation, increased ROS, and decreased MMP indicate potent apoptosis activation. Similar results were observed using mononuclear cells from leukemia patients but not from healthy donors. The SAPK/JNK signaling pathway was strongly activated by the combination treatments, whereas the PI3K/mTOR and Wnt/β- catenin pro-survival pathways were inhibited. These drug combinations may be used in cytoreductive clinical trials for AML patients.
|
Authors | Benigno C Valdez, Bin Yuan, David Murray, Yago Nieto, Uday Popat, Borje S Andersson |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 63
Issue 7
Pg. 1634-1644
(07 2022)
ISSN: 1029-2403 [Electronic] United States |
PMID | 35188042
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
|
Chemical References |
- Anthracenes
- Bridged Bicyclo Compounds, Heterocyclic
- Phthalazines
- Piperazines
- Sulfonamides
- bisantrene
- Decitabine
- Panobinostat
- venetoclax
- olaparib
|
Topics |
- Anthracenes
- Apoptosis
- Bridged Bicyclo Compounds, Heterocyclic
- Cell Line, Tumor
- Decitabine
(pharmacology, therapeutic use)
- Drug Synergism
- Humans
- Leukemia, Myeloid, Acute
(genetics)
- Panobinostat
(pharmacology, therapeutic use)
- Phthalazines
- Piperazines
- Sulfonamides
|